ABUS – Arbutus Biopharma Corporation

ABUS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

12.51

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

EPS Last/This Y

1.2

EPS This/Next Y

-1.15

Price

4.62

Target Price

5.5

Analyst Recom

Performance Q

6.44

Upside

130.2%

Beta

0.61

Ticker: ABUS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	ABUS	4.66	0.20	0.15	12540
2026-07-14	ABUS	4.61	0.20	0.67	12560
2026-07-15	ABUS	4.56	0.21	0.01	12663
2026-07-16	ABUS	4.74	0.19	5.13	13680
2026-07-17	ABUS	4.55	0.32	0.27	15274
2026-07-20	ABUS	4.41	0.41	2.29	12589
2026-07-21	ABUS	4.51	0.48	0.13	13214
2026-07-22	ABUS	4.32	0.47	0.01	13440
2026-07-23	ABUS	4.47	0.45	0.09	13871
2026-07-24	ABUS	4.38	0.45	0.00	13900
2026-07-27	ABUS	4.41	0.44	0.00	14195
2026-07-28	ABUS	4.42	0.44	0.02	14243
2026-07-29	ABUS	4.28	0.43	0.00	14414
2026-07-30	ABUS	4.41	0.43	0.20	14324
2026-07-31	ABUS	4.34	0.43	0.17	14378
2026-08-03	ABUS	4.36	0.43	0.00	14467
2026-08-04	ABUS	4.43	0.43	0.00	14464
2026-08-05	ABUS	4.61	0.41	0.04	14950
2026-08-06	ABUS	4.53	0.41	0.00	15022
2026-08-07	ABUS	4.61	0.41	0.00	15023
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	ABUS	4.66	-100.0	-	-0.22
2026-07-14	ABUS	4.60	-100.0	-	-0.22
2026-07-15	ABUS	4.56	-100.0	-	-0.22
2026-07-16	ABUS	4.74	-100.0	-	-0.22
2026-07-17	ABUS	4.55	-100.0	-	-0.22
2026-07-20	ABUS	4.42	-100.0	-	-0.22
2026-07-21	ABUS	4.51	-100.0	-	-0.22
2026-07-22	ABUS	4.32	-100.0	-	-0.22
2026-07-23	ABUS	4.46	-100.0	-	-0.22
2026-07-24	ABUS	4.38	-100.0	-	-0.22
2026-07-27	ABUS	4.41	-100.0	-	-0.22
2026-07-28	ABUS	4.42	-100.0	-	-0.22
2026-07-29	ABUS	4.28	-100.0	-	-0.22
2026-07-30	ABUS	4.42	-100.0	-	-0.22
2026-07-31	ABUS	4.35	-100.0	-	-0.22
2026-08-03	ABUS	4.35	-100.0	-	-0.22
2026-08-04	ABUS	4.35	-100.0	-	-0.22
2026-08-05	ABUS	4.62	-100.0	-	1.03
2026-08-06	ABUS	4.54	-100.0	-	1.03
2026-08-07	ABUS	4.62	-	-	1.03
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	ABUS	0.00	0.07	10.89
2026-07-14	ABUS	0.00	0.07	10.89
2026-07-15	ABUS	0.00	0.07	10.89
2026-07-16	ABUS	0.00	0.07	10.89
2026-07-17	ABUS	0.00	0.07	10.89
2026-07-20	ABUS	0.00	0.25	10.89
2026-07-21	ABUS	0.00	0.25	10.89
2026-07-22	ABUS	0.00	0.25	10.89
2026-07-23	ABUS	0.00	0.25	10.89
2026-07-24	ABUS	0.00	0.25	10.89
2026-07-27	ABUS	0.00	0.25	12.51
2026-07-28	ABUS	0.00	0.25	12.51
2026-07-29	ABUS	0.00	0.25	12.51
2026-07-30	ABUS	0.00	0.25	12.51
2026-07-31	ABUS	0.00	0.25	12.51
2026-08-03	ABUS	0.00	0.19	12.51
2026-08-04	ABUS	0.00	0.19	12.51
2026-08-05	ABUS	0.00	0.19	12.51
2026-08-06	ABUS	0.00	0.19	12.51
2026-08-07	ABUS	0.00	0.19	12.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.03

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

Institutional Transactions

0.19

Beta

0.61

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

28.9

Max Drawdown 5-Year %

-63.4

Target Price

5.5

P/E

5.63

Forward P/E

PEG

P/S

4.78

P/B

3.5

P/Free Cash Flow

EPS

0.82

Average EPS Est. Cur. Y

1.03

EPS Next Y. (Est.)

-0.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

83.95

Relative Volume

0.4

Return on Equity vs Sector %

34.5

Return on Equity vs Industry %

50.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ ABUS Healthcare

$4.63

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

19/25

Volume

11/15

Valuation

8/20

TP/AR

2/10

Options

8/10

RSI

54.2

Range 1M

33.2%

Sup Dist

3.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

19/30

Estimates

3/20

Inst/Vol

4/15

Options

5/10

EPS Yr

541.8%

EPS NY

-112.3%

52W%

63.5%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟡 HOLD +18.8% upside

Quality

30/30

Valuation

5/30

Growth

11/25

Stability

8/10

LT Trend

3/5

Upside

+18.8%

Quality

ABUS — P/E HistoricalBiotechnology

Arbutus Biopharma Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 19

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

ABUS

Latest News

—

Caricamento notizie per ABUS…

stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today

news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance

stock history ABUS – Arbutus Biopharma Corporation invest stock market

stock prices ABUS premarket after hours

ticker ABUS fair value insiders trading

ABUS – Arbutus Biopharma Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y